August 1-3, 2024 | ProSleep 2024 Users Conference | Fairmont Hotel, San Francisco, CA | Register Now
NEW! ProSomnus® RPMO2 OSA Device System. Explore the Innovation
Healthcare Providers
Find a Provider

News Releases

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference.

About ProSomnus
ProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit www.ProSomnus.com.

Investor Contact
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: [email protected]

Media Contact
Heather Whalen
ProSomnus
Phone: +1.925.360.2990
Email: [email protected]

Applicant Form

Thank you for your interest in ProSomnus career opportunities. Please choose your department of interest:

Resume Upload

By submitting this form, you may be contacted by our staff to verify information.

Brian Dow

Chief Financial Officer

Brian Dow is the Chief Financial Officer for ProSomnus® Sleep Technologies. Prior to joining ProSomnus in March of 2023, Mr. Dow served as Chief Financial Officer of Agendia N.V., a $60 million molecular diagnostics company, Senior Vice President and Chief Financial Officer of Pulse Biosciences (NASDAQ: PLSE), a development stage medical device company, and Principal Accounting Officer for Pacific Biosciences (NASDAQ: PACB), a commercial stage developer, manufacturer and provider of next generation sequencing instruments. Mr. Dow started his career as a manager with Ernst & Young.

Mr. Dow holds a B.S. in Management from the Georgia Institute of Technology and is recognized as a licensed certified public accountant by the Washington State Board of Accountancy.

Request Your Provider Portal Login Credentials

Please complete the form. A ProSomnus team member will reach out to you with your unique login credentials.

Request an Appointment